New Alzheimer's antibody enters human testing
NCT ID NCT06247345
Summary
This is the first study in people for a new drug called ADEL-Y01, which is designed to target a harmful protein in the brain linked to Alzheimer's disease. The study will first test single and multiple doses in healthy volunteers to check for safety, and then test multiple doses in people with early Alzheimer's or mild memory problems. The main goal is to see if the drug is safe and how the body processes it, while also looking for early signs of any effect on memory and thinking.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accel Research - Neurostudies
Decatur, Georgia, 30030, United States
-
CenExel ACT
Anaheim, California, 92801, United States
-
Innovation Medical Research
Palmetto Bay, Florida, 33157, United States
-
K2 Medical Research - Orlando
Maitland, Florida, 32751, United States
-
K2 Medical Research - The Villages
Lady Lake, Florida, 32159, United States
-
Quest Research Institute
Farmington Hills, Michigan, 48334, United States
Conditions
Explore the condition pages connected to this study.